This cell cluster may look jumbled, but it is well organized. Called a glomerulus, it’s a cluster of cells from a kidney; it filters and processes blood to maintain proper levels of water, salt, and ...

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

The FDA approved iptacopan (Fabhalta) as the first treatment to reduce proteinuria in adults with complement 3 glomerulopathy ...

The US Food and Drug Administration (FDA) has approved iptacopan (Fabhalta) as the first treatment to reduce proteinuria in ...

The U.S. Food and Drug Administration (FDA) has announced a series of critical updates this week, reflecting its ongoing ...

Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...

An alternative approach, to which we subscribe, involves finding a limited number of biomarkers that identify injury to primary sites in the kidney, such as the glomerulus or the proximal tubule ...

This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal ...

Approximately one to two people per million globally are diagnosed every year with C3G, which occurs when an over-activation of the alternative complement pathway causes deposits of C3 protein to ...